Arcutis Biotherapeutics Inc (ARQT) concluded trading on Wednesday at a closing price of $13.21, with 7.53 million shares of worth about $99.44 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 39.20% during that period and on February 12, 2025 the price saw a gain of about 15.88%. Currently the company’s common shares owned by public are about 117.00M shares, out of which, 103.03M shares are available for trading.
Stock saw a price change of 0.23% in past 5 days and over the past one month there was a price change of -3.08%. Year-to-date (YTD), ARQT shares are showing a performance of -5.17% which increased to 101.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.05 but also hit the highest price of $16.20 during that period. The average intraday trading volume for Arcutis Biotherapeutics Inc shares is 2.00 million. The stock is currently trading 0.61% above its 20-day simple moving average (SMA20), while that difference is down -2.14% for SMA50 and it goes to 26.62% higher than SMA200.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) currently have 117.00M outstanding shares and institutions hold larger chunk of about 103.49% of that.
The stock has a current market capitalization of $1.55B and its 3Y-monthly beta is at 1.51. It has posted earnings per share of -$1.79 in the same period. It has Quick Ratio of 2.38 while making debt-to-equity ratio of 1.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARQT, volatility over the week remained 10.84% while standing at 7.48% over the month.
Stock’s fiscal year EPS is expected to rise by 65.01% while it is estimated to increase by 37.33% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 30, 2024 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by Jefferies stated Arcutis Biotherapeutics Inc (ARQT) stock as a Buy in their note to investors on August 28, 2024, suggesting a price target of $15 for the stock. On January 03, 2024, Mizuho Upgrade their recommendations, while on October 26, 2023, Mizuho Downgrade their ratings for the stock with a price target of $4. Stock get a Neutral rating from Goldman on October 13, 2023.
